Rush Cancer Institute Section of Hematology — Chicago, Illinois

Rush Cancer Institute Section of Hematology is a clinical research site located in Chicago, Illinois, United States 60612-3824.

Crixeo Health Trust Score: 55/100 (POOR). This profile has not yet been claimed by the site owner.

Rush Cancer Institute Section of Hematology has participated in 2 clinical trials.

Therapeutic areas: Multiple Myeloma.

Sponsors: Celgene, Celgene Corporation.

Sponsor Feasibility Report

Trust Score: 55/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rush Cancer Institute Section of Hematology?

Rush Cancer Institute Section of Hematology has a Crixeo Trust Score of 55/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rush Cancer Institute Section of Hematology conducted?

Rush Cancer Institute Section of Hematology has 2 clinical trials on record. Their work covers Multiple Myeloma.

Is Rush Cancer Institute Section of Hematology accredited by Crixeo Health?

Rush Cancer Institute Section of Hematology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rush Cancer Institute Section of Hematology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.